240 / 2894
35. Canivet JL, Larbuisson R, Damas P, et al: Plasma
renin activity and urine beta 2-microglobulin
during and after cardiopulmonary bypass: pulsatile
vs non-pulsatile perfusion. Eur Heart J 11:1079-
1082, 1990.
36. Price RG: Urinary
N
-acetyl-beta-d-glucosamini-
dase (NAG) as an indicator of renal disease. Curr
Probl Clin Biochem (9):150-163, 1979.
37. Mishra J, Ma Q, Prada A, et al: Identification of
neutrophil gelatinase-associated lipocalin as a novel
early urinary biomarker for ischemic renal injury.
J Am Soc Nephrol 14:2534-2543, 2003.
38. Mishra J, Dent C, Tarabishi R, et al: Neutrophil
gelatinase-associated lipocalin (NGAL) as a bio-
marker for acute renal injury after cardiac surgery.
Lancet 365:1231-1238, 2005.
39. Wagener G, Jan M, Kim M, et al: Association
between increases in urinary neutrophil gelatinase-
associated lipocalin and acute renal dysfunction
after adult cardiac surgery.Anesthesiology 105:485-
491, 2006.
40. Mangano DT, Tudor IC, Dietzel C: The risk associa-
ted with aprotinin in cardiac surgery. N Engl J Med
354:353-365, 2006.
41. Wagener G, Gubitosa G, Wang S, et al: Increased
incidence of acute kidney injury with aprotinin use
during cardiac surgery detected with urinary
NGAL. Am J Nephrol 28:576-582, 2008.
42. Stanton BA, Koeppen BM: Elements of renal
function.
In
Berne RM, Levy MN (eds): Physiology,
4th ed. St. Louis, Mosby, 1998, pp 677-698.
43. Schaer GL, Fink MP, Parrillo JE: Norepinephrine
alone versus norepinephrine plus low-dose dopa-
mine: Enhanced renal blood flow with combination
pressor therapy. Crit Care Med 13:492-496, 1985.
44. Haywood GA, Tighe D, Moss R, et al: Goal directed
therapy with dobutamine in a porcine model of
septic shock: Effects on systemic and renal oxygen
transport. Postgrad Med J 67(S1): S36, 1991.
45. Aronson S, Wiencek JG, Feinstein SB, et al:
Assessment of renal blood flow with contrast ultra-
sonography. Anesth Analg 76:964, 1993.
46. Levens NR, Peach MJ, Carey RM: Role of the intra-
renal renin-angiotensin system in the control of
renal function. Circ Res 48:157-167, 1981.
47. Ballerman BJ, Zeidel ML, Gunning ME, et al: Vaso-
active peptides and the kidney.
In
Brenner BM,
Rector FCJ (eds): The Kidney, 4th ed. Philadelphia,
WB Saunders, 1991, pp 510-583.
48. Hricik D, Browning P, Kopelman R, et al: Captopril-
induced functional renal insufficiency in patients
with bilateral renal-artery stenoses or renal-artery
stenosis in a solitary kidney. N Engl J Med 308:373-
376, 1983.
49. Wynckel A, Ebikili B, Melin JP, et al: Long-term
follow-up of acute renal failure caused by angioten-
sin converting enzyme inhibitors. Am J Hypertens
11:1080-1086, 1998.
50. Colson P, Ribstein J, Mimran A, et al: Effect of
angiotensin converting enzyme inhibition on blood
pressure and renal function during open heart
surgery. Anesthesiology 72:23-27, 1990.
51. Genuth SM: The adrenal glands.
In
Berne RM, Levy
EM (eds): Physiology, 4th ed. St. Louis, Mosby, 1998,
pp 930-964.
52. Baylis PH: Posterior pituitary function in health
and disease. Clin Endocrinol Metab 12:747-770,
1983.
53. Edwards RM, Trizna W, Kinter LB: Renal microvas-
cular effects of vasopressin and vasopressin antago-
nists. Am J Physiol 256:F274-F278, 1989.
54. Levenson DJ, Simmons CEJ, Brenner BM: Arachi-
donic acid metabolites, prostaglandins and the
kidney. Am J Med 72:354-374, 1982.
55. Johnston PA, Bernard DB, Perrin NS, et al: Prosta-
glandins mediate the vasodilatory effect of manni-
tol in the hypoperfused rat kidney. J Clin Invest
68:127-133, 1981.
56. Gerber JG, Olsen RD, Nies AS: Interrelationship
between prostaglandins and renin release. Kidney
Int 19:816-821, 1981.
57. Cumming AD: Acute renal failure and sepsis: The-
rapeutic approaches. Nephrol Dialysis Transplant
4:159-163, 1994.
58. Licker M, Morel DR: Inhibitors of the renin angio-
tensin system: Implications for the anaesthesiolo-
gist. Curr Opin Anaesthesiol 11:321-326, 1998.
59. Madeddu P, Emanueli C, El-Dahr S: Mechanisms of
disease: The tissue kallikrein-kinin system in hyper-
tension and vascular remodeling. Nat Clin Pract
Nephrol 3:208-221, 2007.
59a. Gorfinkel HJ, Szidon JP, Hirsch LJ, et al: Renal per-
formance in experimental cardiogenic shock. Am J
Physiol 222:1260-1268, 1972.
60. de Bold AJ, Borenstein HB, Veress AT, et al: A rapid
and potent natriuretic response to intravenous
injection of atrial myocardial extract in rats. Life Sci
28:89-94, 1981.
61. Laragh J: Atrial natriuretic hormone, the renin-
angiotensin axis, and blood-pressure electrolyte
homeostasis. N Engl J Med 313:1330-1340, 1985.
62. Maack T, Camargo MJF, Kleinert HD, et al: Atrial
natriuretic factor: structure and functional proper-
ties. Kidney Int 27:607-615, 1985.
63. Baughman KL: B-type natriuretic peptide—a
window to the heart. N Engl J Med 347:158-159,
2002.
64. Baxter GF: The natriuretic peptides. Basic Res
Cardiol 99:71-75, 2004.
65. Shannon RP, Libby E, Elahi D, et al: Impact of acute
reduction in chronically elevated left atrial pressure
on sodium and water excretion. Ann Thorac Surg
46:430-437, 1988.
66. Goldberg L, Rajfer S: Dopamine receptors: Applica-
tions in clinical cardiology. Circulation 72:245-248,
1985.
67. Bello-Reuss E, Higashi Y, Kaneda Y: Dopamine
decreases fluid reabsorption in the straight por-
tions of the rabbit proximal tubule. Am J Physiol
242: (Renal Fluid Electrolyte Physiol): F634-F640,
1982.
68. Olsen NV: Effects of dopamine on renal haemo-
dynamics tubular function and sodium excretion
in normal humans. Dan Med Bull 45:282-297,
1998.
69. Eklof AC: The natriuretic response to a dopamine
DA1 agonist requires endogenous activation of
dopamine DA2 receptors. Acta Physiol Scand
160:311-314, 1997.
70. Holtbäck U, Kruse MS, Brismar H, et al: Intrare-
nal dopamine coordinates the effect of antina-
triuretic and natriuretic factors. Acta Physiol
Scand 168:215-218, 2000.
71. Correa AH, Choi MR, Gironacci M, et al: Atrial
natriuretic factor decreases renal dopamine turno-
ver and catabolism without modifying its release.
Regul Pept 146:238-242, 2008.
72. Sansoe G, Ferrari A, Baraldi E, et al: Dopaminergic
control of renal tubular function in patients with
compensated cirrhosis. Dig Dis Sci 47:392-400,
2002.
73. Steudel W, Hurford WE, Zapol WM: Inhaled nitric
oxide: Basic biology and clinical applications.Anes-
thesiology 91:1090-1121, 1999.
74. Brezis M,Heyman SN,Dinour D,et al: Role of nitric
oxide in renal medullary oxygenation: studies in
isolated and intact rat kidneys. J Clin Invest 88:390-
395, 1991.
75. Ito S, Carretero OA,Abe K: Nitric oxide in the regu-
lation of renal blood flow. New Horizons 3:615-623,
1995.
76. Lieberthal W: Biology of ischemic and toxic renal
tubular cell injury: Role of nitric oxide and the infla-
mmatory response. Curr Opin Nephrol Hypertens
7:289-295, 1998.
77. Landin L, Lorente JA, Renes E, et al: Inhibition of
nitric oxide synthesis improves the vasoconstrictive
effect of noradrenaline in sepsis. Chest 106:250-256,
1994.
78. Goligorsky MS, Noiri E: Duality of nitric oxide in
acute renal injury. Semin Nephrol 19:263-271,
1999.
79. Noiri E, Peresleni T, Miller F, et al: In vivo targeting
of inducible NO synthase with oligodeoxynucleoti-
des protects rat kidney against ischemia. J Clin
Invest 97:2377-2383, 1996.
80. Molitoris BA: Transitioning to therapy in ischemic
acute renal failure. J Am Soc Nephrol 14:265-267,
2003.
81. Agmon Y, Peleg H, Greenfeld Z, et al: Nitric oxide
and prostanoids protect the renal outer medulla
from radiocontrast toxicity in the rat. J Clin Invest
94:1069-1075, 1994.
82. Ecoffey C, Edouard A, Pruszczynski W, et al: Effects
of epidural anesthesia on catecholamines, renin
activity and vasopressin changes induced by tilt in
elderly men. Anesthesiology 62:294-297, 1985.
83. Gamulin Z, Forster A, Simonet F, et al: Effects of
renal sympathetic blockade on renal hemodyna-
mics in patients undergoing major aortic abdomi-
nal surgery. Anesthesiology 65:688-692, 1986.
84. Sener M, Torgay A, Akpek E, et al: Regional versus
general anesthesia for donor nephrectomy: Effects on
graft function. Transplant Proc 36:2954-2958, 2004.
85. Gelman S, Gowler KC, Smith LR: Regional blood
flow during isoflurane and halothane anesthesia.
Anesth Analg 63:557-565, 1984.
86. Priano LL: Alteration of renal hemodynamics by
thiopental, diazepam and ketamine in conscious
dogs. Anesth Analg 61:853-862, 1982.
87. Cousins MJ,Mazze RI: Methoxyflurane nephrotoxi-
city: A study of dose response in man. JAMA
225:1611-1616, 1973.
88. Mazze RI, Cousins MJ, Barr GA: Renal effects and
metabolism of isoflurane in man. Anesthesiology
40:536-542, 1974.
89. Eger EI, Koblin DD, Bowland T, et al: Nephrotoxi-
city of sevoflurane versus desflurane anesthesia in
volunteers. Anesth Analg 84:160-168, 1997.
90. Eger EI, Gong D, Koblin DD, et al: Dose-related
biochemical markers of renal injury after sevoflu-
rane versus desflurane anesthesia in volunteers.
Anesth Analg 85:1154-1163, 1997.
91. Bito H, Ikeuchi Y, Ikeda K: Effects of low-flow sevo-
flurane anesthesia on renal function. Anesthesio-
logy 86:1231-1237, 1997.
92. Kharasch ED, Frink EJJ, Zager R, et al: Assessment
of low-flow sevoflurane and isoflurane effects on
renal function using sensitive markers of tubular
toxicity. Anesthesiology 86:1238-1253, 1997.
93. Ebert TJ,Frink EJ,Kharasch ED:Absence of bioche-
mical evidence for renal and hepatic dysfunction
after 8 hours of 1.25 minimum alveolar concentra-
tion sevoflurane anesthesia in volunteers. Anesthe-
siology 88:601-610, 1998.
94. Lee HT, Ota-Setlik A, Fu Y, et al: Differential protec-
tive effects of volatile anesthetics against renal
ischemia-reperfusion injury in vivo.Anesthesiology
101:1313-1324, 2004.
95. Kuiper JW,Groeneveld AB,Slutsky AS,et al: Mecha-
nical ventilation and acute renal failure. Crit Care
Med 33:1408-1415, 2005.
240
Fisiología y anestesia
I